Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, comments on CC-92480, a novel cereblon E3 ligase modulator (CELMoD) currently being assessed in combination with standard treatments in CC-92480-MM-002, a Phase I/II study in patients with relapsed/refractory (R/R) multiple myeloma (NCT03989414). Dr Richardson explains that the mechanism of action of CC-92480 is different from that of immunomodulatory drugs (IMiDs). Preliminary data from the cohort treated with a combination of CC-92480, dexamethasone and bortezomib in a dose-escalated fashion is promising, with a response rate (RR) of 74% and manageable side effects. Further results on the efficacy of this combination, as well as on the combination of carfilzomib and CC-92480 are eagerly awaited. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.